POLISCOPE
Back to feed
NewsABC7 News San Francisco (KGO-TV)October 29, 2026San Francisco County

Eli Lilly reports clinical trial results for weight loss drug retatrutide

Photo: ABC7 News San Francisco (KGO-TV)

Eli Lilly announced clinical trial results showing its weekly injection retatrutide achieved more than double the weight loss of Ozempic over 80 weeks in adults with type 2 diabetes. The company plans to submit the drug for FDA approval in early 2027.

Read the full story at ABC7 News San Francisco (KGO-TV)

Why It Matters

A potential new prescription medication could soon expand treatment options for weight management and type 2 diabetes, pending regulatory review.

Key Facts

  • Eli Lilly shared phase 3 clinical trial results for retatrutide involving more than 1,000 adults with type 2 diabetes.
  • Participants taking retatrutide lost an average of 44.3 lbs on the 9mg dose and 47.4 lbs on the 12mg dose over 80 weeks.
  • Participants taking the highest Ozempic 2mg dose lost an average of 20.9 lbs over the same 80-week period.
  • Retatrutide is a once-weekly injection that mimics three hunger-regulating hormones: GLP-1, GIP, and glucagon.
  • Retatrutide lowered A1C by 2.2% compared to 1.8% with Ozempic.
  • Eli Lilly plans to submit retatrutide for FDA approval in early 2027.
  • Novo Nordisk expects FDA approval for its experimental drug CagriSema by the end of the year.
  • Neither retatrutide nor CagriSema are currently FDA approved.

Who's Mentioned